目的 探讨参一胶囊联合羟基喜树碱氯化钠注射液和顺铂注射液治疗晚期非小细胞肺癌的临床研究。方法 选择2017年6月-2018年6月渭南市中心医院收治的68例非小细胞肺癌患者为研究对象，依据随机数表法将所有患者随机分为对照组和治疗组，每组各34例。对照组患者静脉滴注顺铂注射液，75 mg/d，1次/3周；第1~5天静脉滴注羟基喜树碱氯化钠注射液，10 mg/d；治疗组患者在对照组治疗的基础上口服参一胶囊，2粒/次，2次/d。3周为1个周期，两组患者均治疗2个周期。观察两组的临床疗效，比较两组的生活质量、免疫指标和不良反应。结果 治疗后，对照组和治疗组的临床总缓解率（RR）分别为32.35%、55.88%，疾病控制率（DCR）分别为67.65%、85.29%，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组的生活质量提高率分别为47.06%、67.65%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺均明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗后治疗组患者免疫指标均明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组血细胞降低、恶心呕吐发生情况明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 参一胶囊联合羟基喜树碱氯化钠注射液和顺铂注射液治疗晚期非小细胞肺癌的临床效果较好，可提高患者生活质量，调节免疫功能，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the effects of Shenyi Capsules combined with Hydroxycamptothecin and Sodium Chloride Injection and Cisplatin Injection in treatment of advanced non-small cell lung cancer. Methods Patients (68 cases) with advanced non-small cell lung cancer in Weinan Central Hospital from June 2017 to June 2018 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were iv administered with Cisplatin Injection, 75 mg/d, once every 3 weeks. And at the first to fifth day, patients in the control group were also iv administered with Hydroxycamptothecin and Sodium Chloride Injection, 10 mg/d. Patients in the treatment group were po administered with Shenyi Capsules on the basis of the control group, 2 grains/time, twice daily. A cycle had 3 weeks, and patients in two groups were treated for 2 cycles. After treatment, the clinical efficacies were evaluated, and quality of life, immune indexes, and adverse reactions in two groups were compared. Results After treatment, the RR in the control and treatment groups were 32.35% and 55.88%, respectively, and the DCR in the control and treatment groups were 67.65% and 85.29%, respectively, and there was difference between two groups (P<0.05). After treatment, the improvement rates of quality of life in the control and treatment groups were 47.06% and 67.65%, respectively, and there was difference between two groups (P<0.05). After treatment, CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the immune indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the occurrence situation of hemocytopenia and nausea and vomiting in the treatment group were significantly lower than those in the control group, and there was difference between two groups (P<0.05). Conclusion Shenyi Capsules combined with Hydroxycamptothecin and Sodium Chloride Injection and Cisplatin Injection has clinical curative effect in treatment of advanced non-small cell lung cancer, can improve the quality of life, and regulate the immune function, with good safety, which has a certain clinical application value.

R979.1